3D bioprinting is an innovative technology that promises to revolutionize cancer research and treatment by providing more accurate and complex models of tumor tissue. This advancement is particularly significant in the study of cancers involving the BRCA1 gene. Tumor modeling with 3D bioprinting
The field of regenerative medicine is poised to revolutionize healthcare by 2030. With rapid advancements in stem cell therapy, gene therapy, and tissue engineering, this innovative sector offers groundbreaking treatments for a wide array of health conditions. From chronic diseases to injuries and
The integration of CRISPR technology with biomaterials engineering offers a promising avenue for safer and more effective gene therapies. Tomas Gonzalez-Fernandez, an assistant professor at Lehigh University, has received funding from the National Science Foundation’s Faculty Early Career
Aspect Biosystems, a pioneer in the field of bioprinted tissue therapeutics, recently closed a $115 million Series B financing round aimed at advancing its groundbreaking technology in regenerative medicine. This achievement, led by Dimension and supported by investors such as Novo Nordisk and
The advancements in muscle regeneration technology by Swiss biotech company MUVON Therapeutics are making waves, especially in the realm of treating stress urinary incontinence in women. This breakthrough holds the potential to improve the quality of life for millions while extending healthspan.
In the laboratories of Matricelf, located in Nes Ziona, Israel, an innovative development endeavor is underway, holding the potential to revolutionize the treatment of spinal cord injuries. Established in 2019 by Professor Tal Dvir and Dr. Alon Sinai, Matricelf is at the forefront of creating
